Top 10 global pharmaceutical companies in 2025: K-drug's dominant position is hard to shake, while semaglutide is rising strongly! Where is the next opportunity?
- Share
- Issue Time
- May 13,2025
Summary
Top 10 global pharmaceutical companies by 2025 (based on each company's 2024 revenue data).
1. Merck&Co. (USA) • Revenue
$64.17 billion • Core products: PD-1 inhibitor Keytruda (2024 sales of $29.5 billion), HPV vaccine Gardasil ($8.6 billion).
2. Pfizer (USA)
Revenue: $63.63 billion • Non COVID-19 products showed strong performance: anticoagulant Eliquis ($7.4 billion), pneumonia vaccine Prevnar ($6.4 billion).
3. Johnson&Johnson (USA)
Revenue: $57.07 billion • Main growth point: Darzalex, a multiple myeloma drug ($11.7 billion).
4. AbbVie (USA)
Revenue: $56.33 billion • Successful transformation: Skyrizi, a new generation of immunotherapy drug ($11.7 billion), replaces Humira.
5. AstraZeneca (UK)
Revenue: 54.07 billion US dollars • Key areas: tumor drugs Enhertu and Farxiga (7.7 billion US dollars).
6. Roche (Switzerland)
Revenue: $52.45 billion • Innovative product: ophthalmic dual antibody Vabysmo.
7. Novartis (Switzerland)
Revenue: $50.32 billion • Core pipeline: heart failure drug Entresto, CAR-T therapy Kymriah.
8. Bristol Myers Squibb (BMS) (USA)
Revenue: $48.3 billion • Dependent product: anticoagulant Eliquis ($12.2 billion).
9. Eli Lilly (USA)
Revenue: $45.04 billion • GLP-1 drug: Zepbound, with sales exceeding $30 billion.
10. Sanofi (France) ◦ Revenue: $44.47 billion ◦ Vaccine business: Influenza vaccines and pediatric vaccines continue to contribute revenue.
Pilot Platform: Connecting the Key Hub of the "Last Mile" of Biological Manufacturing (with Avoiding Pits Guide and Cost Estimation Table)
How are Chinese pharmaceutical companies performing? Chinese biopharmaceuticals: Focusing on the fields of liver disease and cancer, accelerating international layout.
Jiangsu Hengrui Pharmaceutical: R&D investment accounts for over 20%, and the overseas authorization amount of PD-1 inhibitor Carilizumab has exceeded 1 billion US dollars.
Shanghai Pharmaceuticals: Leveraging its advantages in raw materials to transform into biopharmaceuticals, with international production bases covering Europe, America, Asia, and Africa.
A noteworthy phenomenon is the rise of Novo Nordisk and Eli Lilly! Novo Nordisk has significantly increased its ranking with sales of $29.296 billion from its three products, Ozempic, Wegovy, and Rybelsus.
Eli Lilly jumped from 12th place in 2024 to 9th place with sales of Mounjaro and Zepbound reaching $16.466 billion.
Unveiled: Did you choose the right 4 weight loss pills? Can I apply for medical insurance? The side effects are significant! Mounjaro Wegovy Zepbound！
The explosive growth of these two companies marks that the GLP-1 field has become a new strategic high ground in the global pharmaceutical industry - the GLP-1 market size will exceed $50 billion in 2024 and is expected to reach $150 billion by 2030.
However, at the same time, Merck's Keytruda (patent expires in 2028) and Novo Nordisk's semaglutide (patent expires in 2032) are facing competition pressure from generic drugs, and companies are accelerating their pipeline expansion.
